Since the approval of such vaccines containing acellular pertussis antigens in 1997, only one manufacturer (sanofi pasteur) has provided this combination vaccine to Canadians, as Pentacel®. NACI members and liaison members conduct themselves within the context of the Public Health Agency of Canada's Policy on Conflict of Interest, including yearly declaration of potential conflict of interest.Ĭombination vaccines against diphtheria, pertussis, polio, tetanus and Haemophilus influenzae type b (Hib) infections have become the standard for routine primary immunization of infants in Canada 1. Manufacturer(s) have sought approval of the vaccine(s) and provided evidence as to its safety and efficacy only when it is used in accordance with the product monographs. Recommendations for use and other information set out herein may differ from that set out in the product monograph(s) of the Canadian manufacturer(s) of the vaccine(s).
People administering the vaccine should also be aware of the contents of the relevant product monograph(s).
The Public Health Agency of Canada acknowledges that the advice and recommendations set out in this statement are based upon the best current available scientific knowledge and is disseminating this document for information purposes. The National Advisory Committee on Immunization (NACI) provides the Public Health Agency of Canada with ongoing and timely medical, scientific and public health advice relating to immunization.
0 kommentar(er)
